Abstract The recent emergence of multimodality imaging, particularly the combination of PET and MRI, has led to excitement over the prospect of improving detection of disease. Iron oxide nanoparticles have become a popular platform for the fabrication of PET/MRI probes owing to their advantages of high MRI detection sensitivity, biocompatibility, and biodegradability. In this article, we report the synthesis of dextran-coated iron oxide nanoparticles (DIO) labeled with the positron emitter 64 Cu to generate a PET/MRI probe, and modified with maleic anhydride to increase the negative surface charge. The modified nanoparticulate PET/MRI probe (MDIO-64 Cu-DOTA) bears repetitive anionic charges on the surface that facilitate recognition by scavenger receptor type A (SR-A), a ligand receptor found on activated macrophages but not on normal vessel walls. Cu-DOTA has an average iron oxide core size of 7-8 nm, an average hydrodynamic diameter of 62.7 nm, an r 1 relaxivity of 16.8 mM -1 s -1 , and an r 2 relaxivity of 83.9 mM -1 s -1 (37°C, 1.4 T). Cell studies confirmed that the probe was nontoxic and was specifically taken up by macrophages via SR-A. In comparison with the nonmodified analog, the accumulation of MDIO in macrophages was substantially improved. These characteristics demonstrate the promise of MDIO-64 Cu-DOTA for identification of vulnerable atherosclerotic plaques via the targeting of macrophages.
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Introduction
Accurate and early diagnosis of disease is an ongoing challenge for current medical imaging technologies. Ideally, detection of disease requires the imaging modality to be capable of detecting pathological events at early stages of progression. Moreover, the imaging method should also be able to provide detailed anatomic information (in high spatial resolution) on the location of these events. The combination of both high detection capability and high resolution is often beyond the scope of any available single imaging modality [1] . For example, among the noninvasive imaging methods, positron emission tomography (PET) has extremely high detection capability (nanomolar to picomolar), which allows it to locate molecular signatures (biomarkers) of certain diseases usually expressed at low levels (nanomoles per liter to picomoles per liter per gram of tissue) [2] , but its spatial resolution is low (1-2 mm). In contrast, magnetic resonance imaging (MRI) can provide high spatial resolution (micrometers) and excellent soft tissue contrast, but has inherently low detection capability (millimolar to micromolar). Although PET and MRI are quite complementary and the combination of PET and MRI has been considered among the most promising pairings to satisfy the ideal traits required for diagnostic imaging, the first prototype MRI/PET system was developed and the first in vivo images were reported only a few years ago [3] . Since then there has been an explosion in interest in developing hybrid PET/MRI systems with the aim of maximizing the synergy of combining the two modalities for early disease diagnosis in vivo [4] [5] [6] [7] [8] .
Parallel to the rapid growth of PET/MRI instrumentation has been a surge in the development of multifunctional probes for dual-modality imaging [9] [10] [11] [12] [13] [14] [15] . Most of the PET/MRI probes reported to date have been on the nanoscale. Nanoparticulate probes have a number of desirable traits for integrating diverse functionalities into a single entity, including the ability to carry a high payload of signal-enhancing/generating materials, easy surface functionalization chemistry for biocompatibility and biomarker targeting, and long blood circulation halflives. These capabilities could substantially improve the sensitivity, specificity, and quality of medical/clinical diagnostic imaging. The biocompatibility and biodegradability profiles of iron oxide nanoparticles (IONPs) have resulted in their becoming an important class of materials for fabricating PET/MRI probes [11] [12] [13] [14] [15] . PET radionuclide-labeled IONPs have been investigated with PET/MRI to detect molecular biomarkers of specific diseases.
For example, IONPs have been developed to image plaque-associated macrophages, which are one of the hallmarks of vulnerable atherosclerotic plaques (VAPs) [16] . VAP rupture is considered the primary cause of acute clinical events such as myocardial infarction and stroke [17] [18] [19] [20] . Macrophage accumulation in plaques has been associated with the degree of instability. Radiolabeled, nonspecific IONPs have been found to accumulate in macrophages found in atherosclerotic plaques [16] . In most cases, uptake of IONPs by macrophages relies on macrophage phagocytosis, which is a nonspecific process. Nonspecific nanoparticulate probes exhibit a differential distribution in the body, primarily because of relative tissue permeability, but they lack targeting specificity, and this results in low labeling efficiency [21] .
Efficient labeling of VAP macrophages can be achieved by decorating nanoparticulate probes with ligands that have both affinity and specificity for macrophage surface ligand scavenger receptors (SRs). Macrophage SR biology was highlighted three decades ago when Brown and Goldstein found that the rate of 125 I-labeled-acetyl-LDL uptake and degradation by resident mouse peritoneal cells was 20 times higher than that of 125 I-labeled native LDL uptake [22, 23] . SRs are not downregulated with increasing ligand concentration. They mediate very efficient and rapid internalization of bound ligands, and repeatedly recycle via endocytic compartments, allowing accumulation of SR-targeted probes inside the cell, thus resulting in the probes being enriched in activated macrophages [24] . SR type A (SR-A) is a receptor that is overexpressed on the surface of activated atheroma macrophages but that is not found on normal vessel walls. SR-A localizes in the cap and interior in lesions at all stages of atheromas and therefore is an attractive target for diagnostic imaging probes [25] .
The common characteristic of all known SR-A ligands, such as oxidized LDL, maleylated LDL, maleylated bovine serum albumin, maleylated polysaccharides, sulfated polysaccharides, and polyinosinic acid, is the repetitive anionic surface charge distribution. SR-A contains a number of overlapping binding sites for ligands, with different binding affinities for each of them [25] [26] [27] [28] . We have previously developed positron emitter 64 Cu-labeled, dextran sulfate coated IONPs (SDIO) for PET/MRI of macrophages in inflamed plaques [29, 30] . Cell studies confirmed that these probes were specifically taken up by activated macrophages in comparison with nontargeted probes [30] . In vivo PET/MRI of a rat injury model showed that probe-enhanced contrast was observed at sites of vascular inflammation, but not in normal vessel walls, in both PET and MRI images [31] . Encouraged by these results, we describe herein the development of an SR-Atargeted, dual-modality PET/MRI probe that utilizes a different targeting ligand, maleylated dextran-coated IONPs (MDIO). The ability of MDIO to target activated macrophages was tested in vitro in cell studies, and the efficiency of 64 Cu labeling of IONPs was evaluated in solutions.
Materials and methods
Materials were obtained from commercial suppliers and used directly, unless otherwise noted. Dextran (from Leuconostoc mesenteroides, average molecular weight 9,000-11,000) was purchased from Sigma-Aldrich. pIsothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4, 7,10-tetraacetic acid (p-SCN-Bn-DOTA, C 24 H 33 N 5 O 8 SÁ 2.5HClÁ2.5H 2 O, purity at least 94 %) was purchased from Macrocyclics. 5-(and 6)-Carboxytetramethylrhodamine succinimidyl ester [5(6)-TAMRA-SE; absorption 546 nm/ emission 575 nm] was purchased from AnaSpec. Copper-64 chloride solution (half-life 12.7 h) (Washington University) was used as received. Spectra/Por Ò dialysis membrane (molecular weight cutoff 50,000) was purchased from Spectrum Laboratories. P388D1 macrophages and RPMI-1640 medium were obtained from American Type Culture Collection (ATCC). Fetal bovine serum, L-glutamine, phosphate-buffered saline (PBS) (19) , and C 12 -resazurin were purchased from GIBCO. Lipoprotein-deficient bovine serum (LPDS) was obtained from Biomedical Technologies (Stoughton, MA, USA). Water was purified using a Millipore Milli-Q Synthesis purifier (18.0 MX cm, Barnstead).
MDIO synthesis
Dextran-coated IONPs (DIO) were synthesized as previously reported with slight modifications [32] . Briefly, a solution of reduced dextran (1 equiv, 400 mg, 0.04 mmol) and FeCl 3 Á6H 2 O (27 equiv, 292 mg, 1.08 mmol) in degassed deionized water (18 mL) was prepared in a 50-mL, two-necked round-bottom flask. The solution was stirred in an ice-water bath for 30 min while argon was bubbled through it. A solution of FeCl 2 Á4H 2 O (18 equiv, 143 mg, 0.72 mmol) in degassed deionized water (4 mL) was prepared and chilled in an ice-water bath for 10 min, and then the solution was added to the flask using a syringe. Five minutes after the Fe 2? solution had been added, chilled (in an ice-water bath) NH 4 OH [432 equiv, 673 lL (606 mg) 17.28 mmol] was added to the flask dropwise with a syringe within 5 min under rapid stirring. The icewater bath was removed. The solution was heated to 85°C. The reaction was kept at 85 ± 5°C for 2 h (argon flow may stop 2-3 min after the temperature reaches 85°C). After it had cooled to room temperature, the solution was loaded into a Spectra/Por Ò dialysis membrane bag (molecular weight cutoff 50,000) and was dialyzed for 72 h against deionized water (eight to ten changes of water). Finally, the solution in the bag was collected, concentrated by centrifugation, and lyophilized to give a brown solid.
Cross-linking and amination of the dextran coating of DIO followed the literature method with slight modifications [33] . Briefly, DIO (104 mg), NaOH pellets (209 mg), and deionized water (2 mL) were added to a 10-mL roundbottomed flask. The mixture was stirred for 30 min, during which time the solution became homogeneous and cooled to room temperature. Epichlorohydrin (0.4 mL) was added to the flask. After the mixture had been stirred for 24 h, the solution was dialyzed for 72 h against deionized water (Spectra/Por Ò dialysis membrane, eight to ten changes of water). The solution was lyophilized to give a brown solid. The solid was transferred into a 50-mL round-bottomed flask. Ammonium hydroxide (25 mL) was added to the flask and the mixture was stirred for 24 h. The solution was concentrated by rotary evaporation. The residue was diluted and dialyzed for 72 h against deionized water (Spectra/ Por Ò dialysis membrane, eight to ten changes of water). The solution was lyophilized to yield a brown solid (103 mg).
Aminated DIO (135 mg), p-SCN-Bn-DOTA (6.71 mg), and 0.1 M sodium borate buffer solution (2 mL) were mixed in a 10-mL round-bottomed flask. Approximately five drops of NaOH aqueous solution (1 N) were added to the flask to bring the pH to 8.5. The mixture was stirred for 24 h. Solid maleic anhydride (2.211 g in total) was added in aliquots to the buffered well-stirred solution in the flask while maintaining the pH. The maleic anhydride dissolved slowly, and the rate of addition of the aliquots was governed by the disappearance of the solid material in the reaction system. The pH of the solution in the flask was monitored continuously and was adjusted to 8.5-9.0 by the addition of solid sodium carbonate. The reaction was complete when no further acid was liberated, i.e., the pH of the solution was stable [34] . The solution was dialyzed against deionized water for 72 h (eight to ten changes of water). The solution was lyophilized to give a brown solid (MDIO-DOTA, 143 mg).
Copper-64 labeling of MDIO MDIO (26.15 mg) was dissolved in 150 lL of 0.1 M pH 7.0 triethanolamine acetate buffer solution in a 1.5-mL Eppendorf vial. Then copper-64 chloride solution (79.67 MBq) was added to the vial and the mixture was vortexed for 5 s to obtain a homogeneous solution. The solution was incubated in a dry bath incubator (Fisher Scientific) for 45 min at 55-60°C. Ethylenediaminetetraacetic acid (EDTA) aqueous solution (22 lL, 100 mM) was added to the vial. After the mixture had been vortexed for 5 s to give a homogeneous solution, the solution was incubated in the same incubator for 15 min at 55-60°C. The crude product was purified by centrifuge filtration with a 10-kDa Nanosep filtration tube (Millipore, Billerica, MA, USA) (15 min at 14,000 rpm) and washed three times with saline (0.9 %). Each time the washing was removed by centrifuge filtration with a 10-kDa Nanosep filtration tube (10 min at 14,000 rpm). After three washings, the filtration tube was turned over and inserted into a new vial, and the nanoparticles, MDIO-64 Cu-DOTA (approximately 15 lL), were collected by centrifugation (2 min at 1,000 rpm). The radioactive nanoparticles were diluted to 650 lL with saline (0.9 %) and were measured to contain 46.59 MBq of radioactivity. Therefore, the labeling efficiency was 68 % after correction for the natural decay of 64 Cu.
MDIO sizes, zeta potential, spectroscopy, and relaxivity
The iron oxide core size of MDIO and DIO was measured by transmission electron microscopy (TEM) using a Philips CM-12 transmission electron microscope operating at 80 kV. The average core diameter of MDIO or DIO was calculated on the basis of an average of 500 particles from different regions of the grid. The average hydrodynamic particle size and size distribution of MDIO and DIO were measured using dynamic light scattering (DLS) with a Nanotrac 150 particle size analyzer (Microtrac, Montgomeryville, PA, USA). The zeta potentials (f) of MDIO and DIO were measured by determining the electrophoretic mobility using a NICOMP TM 380 ZLS device (Particle Sizing Systems, Santa Barbara, CA, USA) in deionized water at room temperature. The amount of iron in MDIO or DIO was measured with a Varian AA 220FS atomic absorption spectrophotometer using an air/acetylene flame. Fourier transform IR spectra were collected with a Shimadzu IR Prestige 21 spectrophotometer. Absorption spectra were measured with a Varian Cary 100-Bio UV-vis spectrophotometer at room temperature. Fluorescence spectra were measured with a HORIBA Jobin Yvon FluoroMax-P spectrophotometer at room temperature.
Longitudinal (T 1 ) and transverse (T 2 ) relaxation times of MDIO and DIO solutions and cell lysates containing MDIO or DIO were measured at 60 MHz (1.4 T) and 37°C with a minispec mq60 (Bruker, Billerica, MA, USA) by the methods we used previously [30] . Briefly, six stock solutions, three for MDIO and three for DIO, were prepared by dissolving 5.00 mg of MDIO or DIO in 1 mL of pH 7.0 deionized water. The concentration of iron was determined by atomic absorption spectroscopy. All solutions were prepared by weight. The MDIO stock solution was diluted 20 times to give the most concentrated MDIO working solution. To match the iron content of the most concentrated MDIO solution, the most concentrated DIO solution which was prepared at 33.5 times dilution. T 1 values were measured using an inversion recovery sequence with ten to 15 data points, and T 2 values were measured using a Carr-Purcell-Meiboom-Gill sequence with s = 1 ms, and 200 data points. Each solution was incubated at 37°C for 10 min before measurement to reach thermal equilibrium. The longitudinal relaxivity (r 1 ) and the transverse relaxivity (r 2 ) were determined as the slope of the line for plots of 1/T 1 or 1/T 2 , respectively, against increasing iron concentration with a correlation coefficient greater than 0.99.
Stability of MDIO-
64 Cu-DOTA MDIO (7.43 mg) was dissolved in 50 lL of 0.1 M pH 7.0 triethanolamine acetate buffer solution in a 1.5-mL Eppendorf vial. As for the labeling described earlier, copper-64 chloride solution (27.1 MBq) was added to the vial and the mixture was incubated for 45 min at 55-60°C. The solution was centrifuged in a 10-kDa Nanosep filtration tube and washed three times with the pH 7.0 buffer solution. The labeling efficiency was 67 %. The purified Cu-DOTA was diluted with 200 lL of 0.1 M pH 7.0 triethanolamine acetate buffer solution in an Eppendorf vial. EDTA aqueous solution (25 lL, 100 mM) was added to the vial. The solution was incubated in a dry bath incubator at 55-60°C for up to 48 h. An aliquot (50 lL) was taken at each time point (1, 4, 24 , and 48 h), and the activity (before purification) was measured using a dose calibrator. Each aliquot was centrifuged and washed three times through a 10-kDa Nanosep filtration tube in order to remove EDTA and EDTA-64 Cu. The final radioactivity (after purification) was measured for the purified Cu-DOTA with a dose calibrator. Comparisons between values were made using a least-squares means t test. Three parallel solutions of Cu-DOTA were prepared for the stability test to provide statistical significance.
In vitro cellular uptake of MDIO and DIO The P388D1 macrophages were maintained in medium (RPMI-1640 with 1 % L-glutamine and 10 % fetal bovine serum) at 37°C in a humidified environment of a 5 % CO 2 atmosphere. When the cells reached 80-90 % confluence, the medium was removed. The cells were scraped down and used for either subculture or cell studies. The P388D1 cells were plated onto 60-mm-diameter tissue culture dishes at 1 9 10 6 cells per milliliter in RPMI-1640 with 1 % L-glutamine and 10 % LPDS (2 mL per dish), and were maintained at 37°C in a humidified environment of a 5 % CO 2 atmosphere overnight, which allowed cells to adhere to the bottom of dishes. Three stock solutions of MDIO or DIO were prepared by dissolving an appropriate amount of nanoparticulate probes in RPMI-1640 with 1 % L-glutamine and 10 % LPDS. The stock solutions were diluted with the same medium to give a series of three solutions with decreasing iron concentration. All solutions were prepared by weight, and iron concentrations were calculated on the basis of the concentration of the stock solution and appropriate dilution factors. After the maintenance medium had been removed, the MDIO or DIO medium solutions (37°C) were introduced to the cells and cells were incubated at 37°C in a 5 % CO 2 atmosphere for 2 h. After removal of the medium, cells were washed with PBS (37°C) (3 9 2 mL for each dish, approximately 2 min for each washing) and were in PBS for confocal imaging, or for the MRI samples, deionized water was added to the dishes (1.2 mL for each dish), and the freezethaw cycle was repeated twice to lyse cells. The cell lysates were placed in 1.5-mL conical tubes and lyophilized. Deionized water (0.3 mL) was added to the residue to generate solutions for relaxation time measurements or MRI [30] .
Specificity of uptake
The P388D1 cells were prepared following the procedure described in ''In vitro cellular uptake of MDIO and DIO.'' The P388D1 cells were incubated with MDIO (100 lM Fe) in the presence of maleylated dextran, dextran sulfate, or dextran in 0-, 0.02-, 0.1-, 0.4-, 1-, and 10-fold excess concentrations, respectively. Cells were incubated at 37°C in a 5 % CO 2 atmosphere for 2 h and then prepared for relaxation time measurements. Cytotoxicity P388D1 cells in RPMI-1640 were plated in 96-well dishes at a concentration of 1.1 9 10 4 cells per well. After overnight incubation in a 5 % CO 2 atmosphere at 37°C, the RPMI-1640 medium was replaced with fresh medium containing various amounts of MDIO. Cells were incubated with MDIO for either 4 or 24 h. The medium was removed and cells were washed with PBS three times; then medium containing C 12 -resazurin (5 lM) was added. After incubation at 37°C in a 5 % CO 2 atmosphere for 15 min, fluorescence was measured using a Safire 2 monochromator microplate reader (Tecan Austria, Grödig, Austria) with excitation at 563 nm and emission at 587 nm. The linearity and limit of detection of the plate reader were checked using fluorescein. Samples were measured in triplicate to provide statistical significance. 
In vitro MRI
MRI was performed with a Biospec 7T system (300 MHz, Bruker, Billerica, MA, USA). The magnet was equipped with the standard gradient set (95 mT m -1 maximum gradient) and a 72 mm internal diameter volume coil. Cell lysates of MDIO or DIO were prepared following literature methods [30] . The parameters were a repetition time of 1,000 ms and an echo time of 40 ms for T 2 -weighted images. For all images, a spin echo sequence was used with a field of view of 3.44 9 3.06 cm 2 , a slice thickness of 2.0 mm, and a 128 9 128 matrix.
Results and discussion

Synthesis of
64 Cu-labeled MDIO
The synthetic route to obtain 64 Cu-labeled MDIO is illustrated in Scheme 1. DIO were synthesized as previously reported with slight modifications [32] . The dextran coating of the nanoparticles was cross-linked and aminated to generate a stronger nucleophile, amino group functionalized DIO, for conjugation with the 64 Cu chelator, p-SCN-Bn-DOTA [33] . The acylation of DIO-DOTA by maleic anhydride was performed in pH 8.5 borate buffer solution. Because the electron-rich double bond in maleic anhydride hinders the nucleophilic attack of the amino group, and the reaction of maleic anhydride with amines is competitive with hydrolysis of maleic anhydride, particularly at high pH, a high concentration of maleic anhydride was used by addition of excess solid maleic anhydride in aliquots to push the acylation reaction forward, and the pH of the system was kept at approximately 8.5 by addition of small amounts of solid sodium carbonate to neutralize the large amount of acids generated during maleylation [35] . The isotope 64 Cu has been used as a tracer in studies of multimodality PET/ MRI of atherosclerosis because of its relatively long half-life (12.7 h) [20, 29, 34] , which allows repeated imaging over a few days. Copper is easily and stably coordinated to multidentate macrocyclic compounds such as DOTA (log K ML = 22.3) [36] . Usually the chelation of 64 Cu by DOTA derivatives is performed in pH 5.5 acetic acid-acetate buffer solution [10, 12, 20] . However, maleylation is a reversible reaction and maleyl groups can be removed by hydrolysis under acidic conditions [35] . Therefore, to minimize the loss of macrophage-targeting ligands caused by demaleylation, the chelation of 64 Cu ions by MDIO-DOTA was performed in a neutral (pH 7.0) buffer solution. Uncoordinated free 64 Cu ions were extracted by applying excess EDTA. EDTA solution was added to the reaction vial after MDIO and copper-64 chloride had been mixed and incubated for 45 min at 55-60°C. Then, the solution was incubated for 15 min at 55-60°C. Because the coordination stability constant of DOTA-Cu 2? (log K = 22.3) is much higher than that of EDTA-Cu 2? (log K = 18.7) [36, 37] , uncoordinated free 64 Cu ions in the vial would easily coordinate with EDTA but the 64 Cu ions of DOTA-64 Cu chelates would rarely be pulled out by EDTA under the experimental conditions applied. Therefore, the desired dual-modality PET/MRI probe MDIO-64 Cu-DOTA was obtained. After purification, the radiolabeling yield was 68 %, and the specific activity of MDIO-64 Cu-DOTA was calculated as 48 mCi/lg. The corresponding probe MDIO-Cu-DOTA, which contains nonradioactive copper, was also synthesized and used for probe characterization in solution and cell studies to reduce exposure of personnel to radiation.
Verification of MDIO formation
The formation of MDIO was confirmed by Fourier transform IR spectroscopy. Compared with the IR spectrum of DIO (Fig. 1b) (asymmetrical C=O stretch), and 1,574 cm -1 (asymmetrical -C=C-stretch) were observed, whereas the intensities of the absorptions at 2,878 cm -1 (dextran backbone methylene asymmetrical C-H stretch) and 1,042 cm -1 (C-O stretch) were substantially decreased in the Fourier transform IR spectrum of MDIO (Fig. 1a) [38, 39] . The decrease of iron content (from 17.53 % in DIO to 10.48 % in MDIO) in MDIO further verified successful formation of MDIO.
MDIO size, surface charge, relaxivity, and emission Figure 2a shows a representative TEM image, which reveals the uniform cores in MDIO. The average core diameter (7-8 nm) and morphology of MDIO are similar to those of nonmaleylated DIO [32] , indicating that surface modification has little influence on the iron oxide core of the particles. However, the average hydrodynamic diameter in water increased from 38.1 nm for DIO to 62.7 nm for MDIO (Fig. 2b) (37°C, 1.4 T)] we reported before [30] . This is not unexpected as the sizes of the iron oxide cores were similar for MDIO and SDIO. The properties of MDIO, SDIO [30] , and DIO are summarized in Table 1 to differentiate the three. The zeta potential (f) of MDIO was -37.65 mV in water, a 22.95-mV decrease in comparison with the value for DIO measured under the same conditions (-14.7 mV). The highly charged surface indicates that MDIO should form a stable dispersion and emulsification in water because the double layers with high f values would exert powerful electrostatic repulsion and consequently prevent aggregation resulting from collisions caused by Brownian motion [41] . Repeated measurements on MDIO after 1 year of storage on the shelf at room temperature did not reveal measurable changes in their properties.
Stability of MDIO-64 Cu-DOTA
Although it is necessary to use a 64 Cu chelate with high thermodynamic stability, kinetic inertness of the chelate is probably more important in determining the long-term in vivo stability of the chelate. To confirm that 64 Cu ions remain attached to MDIO during imaging over the 48-h time period, the stability of MDIO-64 Cu-DOTA was tested by subjecting Cu-DOTA to a competitive ligand exchange with EDTA, which is known to have a high affinity for copper (log K Cu-EDTA = 18.7) [37] . The results showed that over time, Cu-DOTA at neutral pH did not lose the radiolabel, confirming the exceptional stability of the chelate (Fig. 3) .
Targeting of P388D1 macrophages by MIDO
In vitro uptake of MDIO-Cu-DOTA by P388D1 murine macrophages was studied to test the ability of MDIO to target macrophages. As a control, we also evaluated uptake of nontargeted DIO, whose properties are similar to those of the commercially available, ultrasmall superparamagnetic iron oxide nanoparticulate MRI contrast agent AMI-227 (Sinerem) [42] , under the same conditions. The P388D1 cells were activated by maintaining the cells with RPMI-1640 medium with 10 % LPDS overnight. Figure 4 presents the T 2 values of the lysates of macrophages incubated for 2 h with increasing concentrations of MDIO or DIO. The mean T 2 values for cell lysates incubated with MDIO were significantly (p \ 0.05) smaller than the mean T 2 values for cell lysates incubated with DIO, which was not as efficient and required higher concentrations to produce the same effect as MDIO, indicating that there was limited uptake of DIO (not a ligand of SR-A) compared with MDIO (a ligand of SR-A). The different uptake of MDIO and DIO by macrophages was also demonstrated by results obtained from fluorescence imaging and T 2 -weighted MRI. A modified dye, 5(6)-TAMRA-SE, was added to the reaction system when conjugating DOTA to MDIO. We chose 5(6)-TAMRA-SE as the fluorophore because it is nontoxic and offers a combination of desirable properties such as good photostability, high extinction coefficient, and high fluorescence quantum yield [43, 44] . The resultant fluorophore-labeled MDIO had a peak emission at 588 nm when excited at 541 nm, a 13-nm redshift in comparison with that of 5(6)-TAMRA [45] . After 2 h incubation with MDIO, strong fluorescence was visible in the P388D1 cells, as shown in Fig. 5 . No fluorescence was observed from blank P388D1 cells (Fig. 5) , verifying that the fluorescence observed after incubation with MDIO arises from the probes and not from autofluorescence from the cells. Cells from a parallel experiment were lysed for T 2 -weighted MRI. The contrast between cell lysate containing MDIO and blank cell lysate is obvious, as shown in Fig. 5 . On the other hand, both the fluorescence image and the T 2 -weighted MRI image (Fig. 5 ) of P388D1 incubated with DIO show that there was limited uptake of DIO compared with MDIO.
Receptor-mediated uptake of MDIO by P388D1 macrophages
If a substrate's uptake is receptor-mediated, excess unlabeled SR-A ligands (polyanionic macromolecules or particles) should compete for uptake. Nonspecific uptake is strictly concentration-dependent and will not be affected by additional ligands in the solution [34] . The specificity for the cellular uptake of MDIO was tested by competition studies in which cells were incubated with a fixed (iron) concentration of MDIO and increasing excess of maleylated dextran (a ligand of SR-A), dextran sulfate (a ligand of SR-A), or dextran (not a ligand of SR-A) [27, 28] . Increasing amounts of competitor maleylated dextran, from 0.02-fold to tenfold excess, substantially reduced macrophage uptake of MDIO as evidenced by increased T 2 values, whereas increasing amounts of dextran or dextran sulfate had little influence on the uptake of MDIO by macrophages, as shown in Fig. 6 . This suggests that there may be overlapping but different binding sites for SDIO and MDIO.
Cytotoxicity of MDIO DIO are classified as biocompatible and a few formulations have been approved for clinical MRI use by the US Food and Drug Administration [40] . However, modulation of nanoparticle surfaces may influence particle uptake and biological responses. Therefore, the biocompatibility of modified nanoparticles should be assessed even if the parent nanoparticles are nontoxic. The C 12 -resazurin viability assay is a commonly used method for the assessment of a material's toxicity toward mammal cells that has shown good reliability. C 12 -resazurin is added to the system after the material has been incubated with cells for a certain period. Nonfluorescent C 12 -resazurin is reduced by viable cells to fluorescent C 12 -resorufin, and the resultant signal intensity is proportional to the number of live cells present [46] . MDIO were applied to P388D1 macrophages in culture and the cell viability was evaluated by the C 12 -resazurin viability assay. Untreated cells served as a negative control. The cell viability was above 96 % after both 4 and 24 h incubation with iron concentrations of MDIO ranging from 0.04 to 10 mM (Fig. 7) , indicating that MDIO are nontoxic to macrophages.
Multimodal probes, visible by different imaging modalities, can aid hybrid approaches for disease diagnosis. For example, a single probe visible by PET and MRI can be used to co-register images. The PET signal may be used to determine, in real time, the location of the probe and aid the selection of the relevant volume to be interrogated by MRI. Several examples of 64 Cu-labeled IONPs for PET/MRI of VAP have been reported [12, 20, 30, [47] [48] [49] . In our previous study, we sulfated DIO, thereby targeting the nanoparticulate agent to SR-A of activated macrophages [30] . Co-registration of the PET signal with the MRI signal at 24 h after injection of SDIO confirmed that the PET signal correlates with the change in MRI signal, verifying localization of the multimodal probe at the aortic valve [31] . The magnetic/radioactive properties and in vitro targeting behaviors of MDIO are highly analogous to those of sulfated DIO, implying the in vivo behaviors of the two agents should be quite similar. This will be the topic of a future study. We demonstrated that both MDIO and SDIO are taken up by macrophages via SR-A. However, as shown in Table 2 , the macrophage targeting ability of MDIO is somewhat weaker than that of our previously reported probe SDIO. In comparison with the lysates of blank macrophages, lysates of macrophages incubated with MDIO showed a steady decrease in T 2 from a low iron concentration (10 lM Fe, 10.8 %) to a high iron concentration (500 lM, 74.8 %). By comparison, a T 2 decrease of 80.2 % was observed when macrophages were incubated with SDIO containing 100 lM iron [30] . These results indicate that MDIO could be an efficient nanoparticulate agent to generate MRI image contrast provided that the proper dose is determined.
Several factors may contribute to the uptake differences observed between SDIO and MDIO. In competitive inhibition experiments, the SR-A ligand dextran sulfate effectively inhibited the uptake of SDIO by macrophages, but barely inhibited the uptake of MDIO. SR-A belongs to a growing family of transmembrane glycoproteins. There are three naturally occurring forms of SR-A, types I-III, which are alternative splice variants of the same gene found on chromosome band 8p22 [50] . Type I SR-A contains a C-terminal SR cysteine-rich domain of 110 amino acids, whereas type II and type III SR-A express a short C-terminus or truncated cysteine-rich domain, respectively. The specific ligand-binding activities usually occur on type I and type II SR-A because SR-A type III is trapped in the endoplasmic reticulum. Although SR-A was originally identified through its specific recognition of modified LDL, it is now known to be able to interact with many diverse ligands containing a repetitive anionic charge distribution. SR-A recognizes and binds these polyanionic ligands via a positively charged stretch of lysines in the collagenous binding domain of the receptor [25] ; therefore, the binding of MDIO and SDIO may occur either at different amino acid segments of the same type of SR-A or on the different types of SR-A [25] . This is consistent with what is known about ligands for SR-A, which exhibits nonreciprocal cross-competition for some ligands [51] . The detailed binding mechanisms may be complex, and exploration of them is ongoing.
Macrophages are present through all stages of atherosclerosis development, and high densities of macrophages have been associated with plaque instability. This makes them attractive markers for targeting diagnostics and therapeutics [52, 53] . Antibodies and peptides with high affinity for macrophage SRs have been attached to imaging probes for targeted imaging of macrophages [54] [55] [56] . Antibodies have been the common targeting molecules for decades [57] . Although current development of monoclonal antibodies has focused on humanized derivatives to decrease their immunogenicity, these large, complex molecules require significant engineering at the molecular level to be effective. The variation from batch to batch further restricts their efficiency as targeting molecules. Peptides can bind targets with high sensitivity and specificity. Peptides are smaller, less immunogenic, stabler (without batch-to-batch variations), and easier to manufacture than antibodies, but they have low serum stability [58] .
Owing to their small size and low cost of production, small molecules have emerged as a new class of targeting molecules and they have shown targeting ability and efficiency comparable to those of traditional targeting ligands [59] . For example, folic acid (folate) has a high affinity for tumors because folate receptors are frequently oveexpressed on tumor cells [59] . A variety of folate-decorated nanoparticles have been used for imaging of and therapy for cancers. We have modified DIO with negatively charged small molecules such as maleate and sulfate to place repetitive anionic charge distribution on the surface of the probe. The results showed that the SR-A-mediated uptake of maleate-and sulfate-modified probes is much more efficient than that of nonmodified analogs, indicating that although maleate and sulfate themselves are not ligands of SR-A, suitable arrangement of them on a nanoparticulate (or a macromolecular) probe could result in the probe being specifically recognized and effectively taken up by SR-A.
As a research tool, the ability to image macrophages in vivo provides a valuable biomarker to assess plaque stability. The ability to evaluate plaque vulnerability would be a new diagnostic tool for clinicians. How this might be used to inform patient treatment is still under consideration. Detection of vulnerability could precipitate prescription of systemic treatment with anti-inflammatory agents. For example, the more complex question is whether to intervene with more invasive procedures: should a clinician implant a stent to treat a plaque or otherwise treat a Corresponding p values are given in parentheses. SDIO data are from [30] NA not available plaque that has not yet ruptured but appears to be very vulnerable? Whether to take action for an asymptomatic patient is a question of some debate. Observing inflammatory changes over time has the potential to help answer this question by allowing clinicians to better understand the natural history of plaque progression and regression. It has been recognized that plaque progression involves repeated cycles of inflammation and remodeling, wherein there may be many ruptures over a period of time before sudden death occurs [60] . However, there is not yet a good mechanism to observe or predict these cycles. Noninvasive imaging provides a powerful tool to observe macrophage burden and plaque size and to help understand plaque progression as well as response to therapies.
Conclusions
Current advances in multimodality imaging allow researchers to gather in vivo anatomic and molecular information from multiple perspectives, providing attractive and practical tools for early and accurate diagnosis of disease. We have synthesized 64 Cu-labeled IONPs and functionalized the nanoparticulate probe with maleic anhydride, thus targeting the dual-modality PET/MRI probe to SR-A of macrophages. Macrophages are key components in the formation and development of VAP whose detection and identification is still a challenge by conventional means. Our results indicate that small molecules could be an effective alternative to target nanoparticulate probes to biomarkers of VAP. This could potentially result in the development of new multimodal imaging probes with small molecules as ligands targeting plaque biomarkers, and thus may result in a new method to synthesize targeted and hybrid imaging probes.
